Everence Capital Management’s Gilead Sciences GILD Stock Holding History

Everence Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.85M	Hold	34,790	–	–	0.3%	54
2025 Q4	$4.27M	Hold	34,790	–	–	0.25%	65
2025 Q3	$3.86M	Hold	34,790	–	–	0.23%	73
2025 Q2	$3.86M	Hold	34,790	–	–	0.25%	64
2025 Q1	$3.9M	Hold	34,790	–	–	0.27%	67
2024 Q4	$3.21M	Buy	34,790 +530	+2%	+$47.7K	0.21%	81
2024 Q3	$2.87M	Sell	34,260 -5,390	-14%	-$411K	0.18%	96
2024 Q2	$2.58K	Hold	39,650	–	–	0.18%	111
2024 Q1	$2.9K	Hold	39,650	–	–	0.19%	102
2023 Q4	$3.21M	Sell	39,650 -1,030	-3%	-$80.2K	0.23%	90
2023 Q3	$3.05K	Buy	40,680 +4,680	+13%	+$360K	0.24%	80
2023 Q2	$2.77M	Sell	36,000 -3,130	-8%	-$250K	0.23%	85
2023 Q1	$3.25K	Sell	39,130 -320	-0.8%	-$26.5K	0.27%	73
2022 Q4	$3.39K	Buy	39,450 +15,900	+68%	+$1.26M	0.29%	66
2022 Q3	$1.45M	Hold	23,550	–	–	0.13%	136
2022 Q2	$1.46M	Hold	23,550	–	–	0.13%	143
2022 Q1	$1.4M	Sell	23,550 -9,100	-28%	-$582K	0.11%	156
2021 Q4	$2.37M	Hold	32,650	–	–	0.18%	101
2021 Q3	$2.28M	Hold	32,650	–	–	0.19%	98
2021 Q2	$2.25M	Hold	32,650	–	–	0.18%	100
2021 Q1	$2.11M	Hold	32,650	–	–	0.19%	94
2020 Q4	$1.9M	Sell	32,650 -11,400	-26%	-$688K	0.19%	91
2020 Q3	$2.78M	Buy	44,050 +9,550	+28%	+$662K	0.31%	58
2020 Q2	$2.69M	Hold	34,500	–	–	0.32%	54
2020 Q1	$2.58M	Hold	34,500	–	–	0.36%	50
2019 Q4	$2.24M	Buy	34,500 +7,530	+28%	+$490K	0.33%	62
2019 Q3	$1.71M	Hold	26,970	–	–	0.28%	83
2019 Q2	$1.82M	Buy	26,970 +3,240	+14%	+$213K	0.3%	75
2019 Q1	$1.54M	Sell	23,730 -6,791	-22%	-$451K	0.27%	88
2018 Q4	$1.91M	Hold	30,521	–	–	0.44%	55
2018 Q3	$2.36M	Hold	30,521	–	–	0.47%	50
2018 Q2	$2.16M	Hold	30,521	–	–	0.46%	51
2018 Q1	$2.3M	Hold	30,521	–	–	0.51%	49
2017 Q4	$2.19M	Buy	30,521 +849	+3%	+$64.5K	0.48%	51
2017 Q3	$2.4M	Buy	29,672 +2,520	+9%	+$193K	0.55%	45
2017 Q2	$1.92M	Hold	27,152	–	–	0.47%	51
2017 Q1	$1.84M	Hold	27,152	–	–	0.48%	51
2016 Q4	$1.94M	Sell	27,152 -2,680	-9%	-$199K	0.56%	45
2016 Q3	$2.36M	Hold	29,832	–	–	0.7%	32
2016 Q2	$2.49M	Buy	29,832 +1,900	+7%	+$169K	0.76%	30
2016 Q1	$2.57M	Hold	27,932	–	–	0.8%	28
2015 Q4	$2.83M	Hold	27,932	–	–	0.92%	23
2015 Q3	$2.74M	Hold	27,932	–	–	0.95%	22
2015 Q2	$3.27M	Hold	27,932	–	–	1.06%	17
2015 Q1	$2.89M	Hold	27,932	–	–	0.97%	20
2014 Q4	$2.63M	Hold	27,932	–	–	0.9%	22
2014 Q3	$3M	Sell	27,932 -3,340	-11%	-$327K	1.1%	18
2014 Q2	$2.59M	Hold	31,272	–	–	0.96%	21
2014 Q1	$2.22M	Hold	31,272	–	–	0.87%	24
2013 Q4	$2.35M	Hold	31,272	–	–	0.95%	24
2013 Q3	$1.97M	Hold	31,272	–	–	0.84%	31
2013 Q2	$1.6M	Buy	+31,272	New	+$1.63M	0.73%	36

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Everence Capital Management's GILD Position: Q1 2026 in Review

Everence Capital Management held its Gilead Sciences (GILD) position steady in Q1 2026 at 34,790 shares worth $4.85M. The position accounts for 0.3% of the portfolio, ranked #54.

Everence Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Everence Capital Management held 34,790 shares of Gilead Sciences worth $4.85M as of Q1 2026.
Everence Capital Management left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.3% of Everence Capital Management's portfolio in Q1 2026, its #54 holding.
Everence Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.